Mesoblast Chief Executive Silviu Itescu welcomed the recognition from the Japanese Government. Mesoblast Limited is an Australian-based regenerative medicine company. Mesoblast seeks to treat ailments in four major areas. On January 14, 2015, Mesoblast confirmed Phase 3 had already begun. In September 2011, Mesoblast entered an agreement with Swiss-based Lonza Group. On August 29, 2018, Mesoblast reported its Annual and Fourth Quarter results. Granted US patent number 8,858,932 provides Mesoblast with exclusive commercial rights through to June 2029. On December 19, 2017, Mesoblast announced that the Phase 3 trial completed enrollment.